June 4, 2011 (Chicago, Illinois) — The aromatase inhibitor exemestane offers a new option for breast cancer prevention in postmenopausal women at high risk for the disease. Data from the Mammary ...

Exemestane modestly enhanced bone loss from the femoral neck without significant influence on lumbar bone loss. Except for a 6% to 9% drop in plasma high-density lipoprotein cholesterol, no major ...

NEW YORK (Reuters Health) - Among postmenopausal women receiving adjuvant therapy for early breast cancer, exemestane is associated with fewer hot flashes than is tamoxifen, but it also causes more ...

Neuropsychological assessments were performed before the start (T1) and after 1 year of adjuvant endocrine treatment (T2) in Dutch postmenopausal patients with BC, who did not receive chemotherapy.

January 18, 2011 — Exemestane used alone for 5 years is similar to exemestane used after 2 to 3 years of tamoxifen in the prevention of relapse in postmenopausal women with hormone-responsive early ...

Selective estrogen-receptor modulators (tamoxifen [Nolvadex, Soltamox], raloxifene [Evista]) have been shown to reduce the risk of breast cancer in postmenopausal women, but also have been associated ...